Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Apr 20;141(1):257–268.e6. doi: 10.1016/j.jaci.2017.03.032

Figure 5.

Figure 5

A&B: Effect of Dex on cytokine-induced MEK1 (MEK) induction. PBMCs from an asthmatic patient were cultured with medium or IL2 plus one of the two epithelial ILC-inducing cytokines—IL33 and TSLP with and without Dex for 5 days. The expression of MEK on gated live lin-CRTH2+ cells was analyzed by FCM. Representative flow cytograms are shown in panel A and cumulative data from 7 asthmatic patients is shown in panel B. C&D: PBMCs were cultured as under Figure 5A and then the frequency of c-Fos+ and pSTAT5+ cells in the live lin-CRTH2+ cell population was assessed. P*<0.05 (paired t test, N=4) as compared to vehicle (V)-treated cells. E: Effect of the MEK inhibitor Trametinib on pSTAT5 in ILCs. PBMCs from allergic asthmatic patients were cultured with medium, IL2/IL33 or IL2/TSLP with and without Trametinib (10 μM) for 5 days and then assessed for pSTAT5. (n=3, *<0.05, paired t test). F: Expression of glucocorticoid receptor (GR) in cytokine-treated cells. PBMCs were cultured with medium, IL2/TSLP or IL2/IL33 for 5 days. The expression of GR was studied in gated live lin-CRTH2+ cells. A representative flow cytogram from one of 3 similar experiments is shown.